Evidence map›Paper›PMID 34867937›Full record

ArticleFrontiers in immunology2021

The NF-κB Transcription Factor c-Rel Modulates Group 2 Innate Lymphoid Cell Effector Functions and Drives Allergic Airway Inflammation.

Barbara C Mindt, Sai Sakktee Krisna, Claudia U Duerr, Mathieu Mancini, Lara Richer, Silvia M Vidal, Steven Gerondakis, David Langlais, Jörg H Fritz

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Aerosol Inhalation of Heat-KilledJournal of immunology research · 2022
    Article
  11. The Role of Nuclear Factor-κB in Cancer Immunity and Immunoediting.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Barbara C MindtMcGill University Research Centre on Complex Traits (MRCCT), Montréal, QC, Canada.
Sai Sakktee KrisnaMcGill University Research Centre on Complex Traits (MRCCT), Montréal, QC, Canada.
Claudia U DuerrCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Microbiology, Infectious Diseases and Immunology, Berlin, Germany.
Mathieu ManciniMcGill University Research Centre on Complex Traits (MRCCT), Montréal, QC, Canada.
Lara RicherDepartment of Pathology, McGill University, Montréal, QC, Canada.
Silvia M VidalMcGill University Research Centre on Complex Traits (MRCCT), Montréal, QC, Canada.
Steven GerondakisBiomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.
David LanglaisMcGill University Research Centre on Complex Traits (MRCCT), Montréal, QC, Canada.
Jörg H FritzMcGill University Research Centre on Complex Traits (MRCCT), Montréal, QC, Canada.
McGill University · CAAustralian Regenerative Medicine Institute · AUCharité - Universitätsmedizin Berlin · DEMcGill Genome Centre · CA

Funding

CIHR 168959CIHR FDN-148405CIHR PJT-175173
6 · The paper itself

Abstract

Group 2 innate lymphoid cells (ILC2s) play a key role in the initiation and orchestration of early type 2 immune responses. Upon tissue damage, ILC2s are activated by alarmins such as IL-33 and rapidly secrete large amounts of type 2 signature cytokines. ILC2 activation is governed by a network of transcriptional regulators including nuclear factor (NF)-κB family transcription factors. While it is known that activating IL-33 receptor signaling results in downstream NF-κB activation, the underlying molecular mechanisms remain elusive. Here, we found that the NF-κB subunit c-Rel is required to mount effective innate pulmonary type 2 immune responses. IL-33-mediated activation of ILC2s

Indexed as

Immunity, InnateAnimalsAsthmaDisease Models, AnimalFemaleGene ExpressionInterleukin-33In Vitro TechniquesLungLymphocyte ActivationLymphocyte SubsetsMiceMice, Inbred C57BLMice, KnockoutNF-kappa BProto-Oncogene Proteins c-relIl33 protein, mouseInterleukin-33NF-kappa BProto-Oncogene Proteins c-relairway inflammationc-Relgroup 2 innate lymphoid cell (ILC2)IL-33type 2 immunity

Identifiers

PMID34867937
PMCPMC8635195
OpenAlexW3212832908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.